Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers
Background and purposeMyelin-oligodendrocyte glycoprotein antibody associated disease (MOGAD) is a common inflammatory disease of the central nervous system (CNS) in children that can lead to demyelination. Evaluation and monitoring of biomarkers associated with its pathogenesis would provide vital...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534172/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087419914027008 |
|---|---|
| author | Xin Wang Ruibin Zhao Jiayu Fan Chong Liu Li Zhang Huafang Yang Weiyi Wang |
| author_facet | Xin Wang Ruibin Zhao Jiayu Fan Chong Liu Li Zhang Huafang Yang Weiyi Wang |
| author_sort | Xin Wang |
| collection | DOAJ |
| description | Background and purposeMyelin-oligodendrocyte glycoprotein antibody associated disease (MOGAD) is a common inflammatory disease of the central nervous system (CNS) in children that can lead to demyelination. Evaluation and monitoring of biomarkers associated with its pathogenesis would provide vital information on disease progression and therapeutic assessment.MethodsWe assessed NLRP3, HMGB1, IL-6, and IL-33 levels in the cerebrospinal fluid (CSF) of pediatric patients with MOGAD at different time points and their association with the risk of disease. We recruited 30 patients with MOGAD (20 in the acute phase and 10 in remission) and 10 control patients with noninflammatory demyelinating disease. The expanded disability status scale (EDSS) was used to assess disease severity.ResultsNLRP3, HMGB1, and IL-6 levels in the CSF were significantly higher in patients with MOGAD during the acute phase than in remission (P < 0.05, P < 0.05, P < 0.05) and the control group (P < 0.01, P < 0.0001, P < 0.01). HMGB1 levels were significantly correlated with NLRP3 levels (P < 0.01) during the acute phase. Moreover, we found notable correlation between HMGB1 levels and EDSS (P < 0.05) scores. IL-6 levels were significantly correlated with the total number of attacks (P < 0.05), but not with EDSS scores.ConclusionsThese findings suggest that NLRP3, HMGB1, and IL-6 in the CSF may be potential therapeutic targets and are at least partly involved in the pathogenesis of pediatric MOGAD. HMGB1 in the CSF may be a potential biomarker correlating with pediatric MOGAD severity. Further investigations are warranted to validate potential cytokine pathways between that NLRP3, HMGB1, and IL-6 of MOGAD. |
| format | Article |
| id | doaj-art-c786ad96066b4c989a65f7ec16e1b0df |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-c786ad96066b4c989a65f7ec16e1b0df2025-02-06T05:21:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15341721534172Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkersXin Wang0Ruibin Zhao1Jiayu Fan2Chong Liu3Li Zhang4Huafang Yang5Weiyi Wang6Second Department of Neurology, Hebei Children’s Hospital, Shijiazhuang, ChinaSchool of Medical Imaging, Hebei Medical University, Shijiazhuang, ChinaSecond Department of Neurology, Hebei Children’s Hospital, Shijiazhuang, ChinaSecond Department of Neurology, Hebei Children’s Hospital, Shijiazhuang, ChinaDepartment of Pathology, Hebei Children’s Hospital, Shijiazhuang, ChinaSecond Department of Neurology, Hebei Children’s Hospital, Shijiazhuang, ChinaSecond Department of Neurology, Hebei Children’s Hospital, Shijiazhuang, ChinaBackground and purposeMyelin-oligodendrocyte glycoprotein antibody associated disease (MOGAD) is a common inflammatory disease of the central nervous system (CNS) in children that can lead to demyelination. Evaluation and monitoring of biomarkers associated with its pathogenesis would provide vital information on disease progression and therapeutic assessment.MethodsWe assessed NLRP3, HMGB1, IL-6, and IL-33 levels in the cerebrospinal fluid (CSF) of pediatric patients with MOGAD at different time points and their association with the risk of disease. We recruited 30 patients with MOGAD (20 in the acute phase and 10 in remission) and 10 control patients with noninflammatory demyelinating disease. The expanded disability status scale (EDSS) was used to assess disease severity.ResultsNLRP3, HMGB1, and IL-6 levels in the CSF were significantly higher in patients with MOGAD during the acute phase than in remission (P < 0.05, P < 0.05, P < 0.05) and the control group (P < 0.01, P < 0.0001, P < 0.01). HMGB1 levels were significantly correlated with NLRP3 levels (P < 0.01) during the acute phase. Moreover, we found notable correlation between HMGB1 levels and EDSS (P < 0.05) scores. IL-6 levels were significantly correlated with the total number of attacks (P < 0.05), but not with EDSS scores.ConclusionsThese findings suggest that NLRP3, HMGB1, and IL-6 in the CSF may be potential therapeutic targets and are at least partly involved in the pathogenesis of pediatric MOGAD. HMGB1 in the CSF may be a potential biomarker correlating with pediatric MOGAD severity. Further investigations are warranted to validate potential cytokine pathways between that NLRP3, HMGB1, and IL-6 of MOGAD.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534172/fullNLRP3HMGB1IL-6MOGADpediatricCSF |
| spellingShingle | Xin Wang Ruibin Zhao Jiayu Fan Chong Liu Li Zhang Huafang Yang Weiyi Wang Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers Frontiers in Immunology NLRP3 HMGB1 IL-6 MOGAD pediatric CSF |
| title | Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers |
| title_full | Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers |
| title_fullStr | Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers |
| title_full_unstemmed | Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers |
| title_short | Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers |
| title_sort | assessing the inflammation in pediatric mogad significance of csf hmgb1 and related biomarkers |
| topic | NLRP3 HMGB1 IL-6 MOGAD pediatric CSF |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534172/full |
| work_keys_str_mv | AT xinwang assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT ruibinzhao assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT jiayufan assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT chongliu assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT lizhang assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT huafangyang assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers AT weiyiwang assessingtheinflammationinpediatricmogadsignificanceofcsfhmgb1andrelatedbiomarkers |